Key Highlights
- New leukopak cell therapy and PBMC processing labs in Springfield, Missouri.
- Expanded clinical trial sample analysis services complement existing bioanalysis capabilities.
- Central laboratory with state-of-the-art technology for comprehensive clinical trial support.
Source: Business Wire
Notable Quotes
- “There is significant unmet demand in this rapidly growing area of cell therapy products, which represents a tremendous opportunity for QPS. Over 3,000 cell and gene therapy programs are currently in progress representing a 20% increase over the past five years.” — Benjamin Chien, Chairman, President, and CEO at QPS
- “These new facilities, services and products extend our full service CRO capabilities, putting QPS in a position to offer clients comprehensive clinical research services in one location.” — Brendon Bourg, Vice President, Early Phase Clinical and Head of Administration at QPS Missouri
SoHC's Take
QPS’s strategic expansion of its laboratory services with new leukopak and PBMC capabilities is a significant move that enhances its position as a leading CRO. The establishment of these facilities in Springfield, Missouri, aligns with the growing demand for cell therapy products and clinical trial support. By leveraging their comprehensive database of potential blood donors and state-of-the-art lab technologies, QPS is well-positioned to meet the increasing needs of the biopharmaceutical industry. This expansion not only complements their existing bioanalysis and clinical services but also strengthens their market presence, ensuring they continue to provide top-tier, integrated solutions to their clients.
